June 29, 2006
Girls Should Get Cancer Vaccine
By Maggie Fox, Health and Science Correspondent
WASHINGTON (Reuters) - Girls as young as 11 and young women up to age 26 should get Merck and Co.'s Gardisil vaccine aimed at preventing a sexually transmitted virus that can cause cancer, a panel of U.S. experts said on Thursday.
In a complicated vote, the Advisory Committee on Immunization Practices (ACIP) agreed to recommend the vaccine for three age groups -- all young girls aged 11 and 12; girls and women aged 13 to 26 who have not received the vaccine yet; and women who have had abnormal pap smears, genital warts, or certain other conditions.
At their discretion, physicians could vaccinate as young as 9, the panel decided.
The ACIP advises the U.S. Centers for Disease Control and Prevention, which in turn advises schools districts and other authorities.
The U.S. Food and Drug Administration licensed Gardasil for use in women and girls 9 to 26 years of age earlier this month. It protects against four types of human papilloma virus, also known as HPV or human wart virus.
The idea is to vaccinate girls before they ever get infected with the virus.
The approval could make for blockbuster sales for Merck, with some analysts predicting annual sales of more than $3 billion within the next few years.
"I think this is going to be a great cancer prevention tool but it is not going to be effective for about 10 years," said Dr. Carol Baker of the national Foundation for Infectious Disease, who was at the meeting.
This is because genital wart infection takes a while to cause cancer.
Clinical trials have shown that a three-dose course of the vaccine can prevent close to 100 percent of the lesions that can become cervical cancer, and genital warts. Women get regular Pap smears in most developed countries to detect these lesions before they turn into tumors.
The virus can also cause much rarer penile cancer in men. The HPV 16 and 18 strains of virus are responsible for about 70 percent of cervical cancer cases.
The CDC has no enforcement powers. It will be up to insurers to decide whether to pay for the $125-a-dose vaccine, school districts and universities to require or recommend it and individuals themselves to decide whether to get it.
Dr. Cynthia Rand of the University of Rochester in New York said she believed most people would get the vaccine. She has started a series of studies on how many people would take the vaccine if offered.
"Most were accepting of the vaccine," Rand said in a telephone interview. "Teens were surprising in that they seemed to know more about HPV than their parents did."
Rand has no hard numbers yet but found no controversy about whether the vaccine might somehow encourage young people to have sex.
"The minority of parents we interviewed didn't think their children wouldn't be needing it because their children wouldn't be having sex. But they thought it would be needed in the general community," she said.
At least one state legislative group, Women In Government, will be supporting the vaccine.
"Many state legislators around the country are ready to support a public health effort that will make sure that all age-appropriate girls and women can receive the HPV vaccine, regardless of their socioeconomic status," said Sarah Wells of the group, a nonprofit, bipartisan organization representing women state legislators.
GlaxoSmithKline also has a slightly different HPV vaccine in development.
The CDC says genital HPV infection is the most common sexually transmitted infection in the United States. More than 50 percent of sexually active women and men will be infected with one or more genital HPV types during their lifetimes.
Merck has already been planning ahead for sales of the vaccine.
"Merck has already been shipping Gardasil since its approval. We model Gardasil sales of $3.2 billion in 2010," said Dr. Tim Anderson, Senior Pharmaceutical Analyst at Prudential Equity Group.